despit
consider
advanc
medic
pharmaceut
research
past
year
diseas
caus
virus
remain
major
burden
public
health
virtual
silico
screen
repeatedli
proven
use
meet
special
challeng
antivir
drug
discoveri
larg
virtual
compound
librari
filter
differ
comput
screen
method
dock
ligandbas
similar
search
pharmacophorebas
screen
reduc
number
candid
molecul
smaller
set
promis
candid
test
biolog
ration
approach
make
drug
discoveri
process
goalori
save
resourc
term
time
money
review
discuss
differ
virtual
screen
techniqu
appli
antivir
drug
discoveri
present
recent
success
stori
field
final
address
main
differ
method
section
editor
viral
infect
result
acut
potenti
lethal
clinic
condit
eg
influenza
dengu
also
chronic
ill
eg
hiv
hepat
c
treat
long
period
time
therefor
lead
high
expens
health
care
system
especi
potenti
viral
infect
reach
pandem
dimens
major
concern
day
primari
challeng
develop
effect
antivir
therapi
high
variabl
viral
genom
make
easi
adapt
new
condit
rapidli
develop
resist
use
drug
fact
demand
fast
effect
drug
discoveri
process
past
decad
comput
techniqu
like
virtual
screen
proven
great
use
make
drug
develop
process
faster
less
expens
applic
virtual
screen
vs
drug
develop
process
viral
target
vari
first
step
target
lead
structur
identif
well
step
like
compound
develop
optim
ration
improv
vs
review
aim
provid
explan
method
commonli
employ
vs
viral
target
overview
latest
find
achiev
research
field
focu
develop
sinc
review
vs
viral
target
date
see
kirchmair
et
al
silico
vs
use
comput
model
describ
macromoleculeligand
interact
multitud
method
exist
purpos
mainli
categor
approach
descriptorbas
method
method
reli
calcul
comparison
scalar
molecular
properti
aim
identifi
molecul
similar
respect
calcul
molecular
attribut
select
weigh
descriptor
relev
certain
target
bind
perform
use
machinelearn
techniqu
neural
network
linear
correl
measur
biolog
activ
quantit
structureact
relationship
qsar
select
calcul
descriptor
recent
comput
approach
discoveri
antivir
compound
reli
method
aim
describ
steric
chemic
complementar
conform
macromolecular
target
bind
ligand
fig
two
approach
develop
model
either
experiment
determin
structur
diseaserelev
macromolecular
biolog
target
structurebas
design
ii
set
ligand
suppos
bind
target
locat
ligandbas
design
structurebas
design
xray
crystallographi
main
sourc
inform
protein
data
bank
pdb
excel
data
sourc
approach
ideal
bind
pocket
locat
alreadi
known
case
ligand
cocrystal
target
structur
ligandbas
design
contrast
employ
case
structur
inform
target
avail
requir
set
alreadi
known
biolog
activ
molecul
whose
common
bind
locat
verifi
experiment
exampl
mutat
studi
allow
search
novel
potenti
ligand
show
similar
overlay
either
term
molecul
volum
molecular
shape
term
chemic
function
hydrogen
bond
donor
acceptor
lipophil
area
charg
method
differ
term
comput
perform
applic
method
show
substanti
lower
calcul
time
therefor
mostli
use
first
classif
filter
reduc
number
molecul
screen
later
stage
structurebas
approach
posit
put
activ
ligand
relev
bind
site
therefor
frequent
abl
provid
idea
chemic
optim
compound
lead
optim
ligandbas
approach
show
advantag
extent
overlay
known
activ
compound
provid
help
analyz
aspect
import
lead
optim
proteinligand
dock
import
structurebas
approach
aim
predict
bind
mode
ligand
protein
known
structur
assum
protein
bind
site
mostli
rigid
ligand
flexibl
sever
dock
tool
avail
review
recent
differ
term
algorithm
use
ligand
placement
score
includ
ligand
fragment
increment
reconstruct
approach
eg
flexx
algorithm
base
molecular
shape
eg
dock
fred
genet
algorithm
eg
gold
autodock
systemat
search
eg
glide
mont
carlo
optim
eg
ligandfit
surfacebas
molecular
similar
eg
surflex
ligand
placement
work
reliabl
sampl
possibl
ligand
bind
geometri
score
function
work
depend
target
mainli
due
imposs
estim
entrop
effect
correctli
nevertheless
manual
develop
empir
score
function
tailor
defin
applic
scope
still
use
due
visual
bind
hypothesi
dock
remain
one
method
provid
mani
idea
ration
lead
optim
pharmacophor
model
base
concept
threedimension
arrang
chemic
featur
hydrogen
bond
charg
lipophil
area
form
pattern
describ
bind
ligand
macromolecul
advantag
pharmacophor
model
easi
interpret
way
modif
allow
research
incorpor
knowledg
specif
bind
mode
transpar
still
highli
descript
model
care
arrang
chemic
featur
marker
space
search
molecul
fulfil
requir
interact
one
success
approach
vs
led
mani
success
stori
retrospect
explan
ligand
affin
subsequ
prospect
ligand
design
ligandbas
pharmacophor
creation
introduc
earli
day
molecular
model
structurebas
pharmacophor
design
introduc
recent
program
ligandscout
deriv
pharmacophor
proteinligand
complex
interpret
ligand
geometri
assign
correct
hybrid
state
appli
set
rule
classifi
plausibl
proteinligand
interact
subsequ
vs
comput
effici
patternmatch
algorithm
implement
allow
geometr
highli
accur
vs
program
catalyst
moe
phase
use
cascad
npoint
pharmacophor
fingerprint
pharmacophoremolecul
superposit
simplic
pharmacophor
represent
also
mean
complet
biophys
natur
drug
interact
address
understand
limit
approach
essenti
success
applic
shapebas
similar
screen
pure
ligandbas
method
allow
search
analog
singl
compound
despit
simplic
power
frequent
use
filter
method
due
straightforward
way
use
one
popular
program
shapebas
search
roc
implement
algorithm
base
gaussian
sphere
compar
molecular
volum
roc
addit
use
basic
pharmacophorelik
similar
scheme
includ
chemic
inform
overlay
result
method
success
use
recent
discoveri
antivir
compound
screen
differ
compound
databas
compound
previous
unknown
antivir
activ
follow
give
overview
success
stori
prospect
discoveri
antivir
compound
use
ration
drug
design
techniqu
vs
extens
inform
mention
public
found
summari
tabl
provid
supplementari
materi
influenza
season
epidem
acut
respiratori
diseas
persist
threaten
public
health
caus
ribonucl
acid
rna
influenza
virus
orthomyxovirida
famili
drug
design
fight
influenza
virus
mainli
target
neuraminidas
na
enzym
enabl
transport
viru
host
mucu
regard
vs
success
use
identifi
novel
inhibitor
target
kirchmair
et
al
report
studi
shape
chemic
featurebas
search
analog
valid
na
inhibitor
katsumadain
perform
nation
cancer
institut
nci
compound
databas
http
cactusncinihgovdownloadnci
five
compound
evalu
nainhibit
potenti
includ
four
flavonoid
demonstr
strong
activ
three
oseltamivirsuscept
strain
micromolar
rang
human
immunodefici
viru
hiv
member
retroviru
famili
caus
acquir
immunodefici
syndrom
aid
one
major
worldwid
health
problem
time
differ
gener
approach
pursu
fight
retroviru
prevent
genet
materi
replic
insert
within
host
cell
ii
block
entri
viru
insid
cell
iii
inhibit
assembl
matur
revers
transcriptas
rt
one
major
target
antiretrovir
drug
therapi
use
treatment
aid
rt
respons
retro
transcript
rna
dna
first
phase
intracellular
viral
replic
attempt
target
protein
bustanji
et
al
select
fragmentlik
compound
nci
databas
perform
high
throughput
dock
select
six
best
hit
test
base
consensu
dock
score
four
found
inhibit
rt
biolog
test
similarli
nichol
et
al
develop
dockingbas
vs
strategi
start
zinc
databas
screen
million
molecul
wildtyp
viral
protein
two
clinic
relev
rtmutant
studi
activ
rt
measur
nine
hit
compound
three
show
lowmicro
molar
antivir
activ
toward
either
one
wildtyp
mutant
strain
anoth
vs
screen
perform
identifi
novel
compound
target
rt
well
viral
function
associ
rna
transcript
shapebas
screen
appli
nci
databas
first
vs
run
use
dihydroxi
benzoyl
naphthyl
hydrazon
known
rt
inhibitor
queri
compound
activ
hit
identifi
process
employ
second
vs
use
combin
ligandbas
strategi
compris
search
ligandbas
pharmacophor
screen
test
rt
function
sever
select
compound
character
new
scaffold
shown
inhibit
rtassoci
ribonucleas
h
rt
activ
low
micromolar
rang
anoth
therapeut
strategi
hiv
inhibit
integr
viral
dna
host
cell
genom
target
integras
recent
targetbas
pharmacophor
search
perform
commerci
databas
lead
hit
compound
select
biolog
investig
one
compound
show
signific
inhibitori
potenc
prove
moder
inhibit
replic
process
hiv
entri
also
inhibit
level
viral
envelop
glycoprotein
bind
receptor
one
chemokin
coreceptor
lalond
et
al
describ
dock
plu
shapebas
similar
search
identifi
aminebuild
block
conjug
core
scaffold
yield
novel
analog
maintain
similar
affin
final
capsid
protein
play
import
role
assembl
matur
recogn
potenti
target
develop
new
gener
drug
antiaid
therapi
curelli
et
al
undertook
dockingbas
vs
subsequ
analog
search
small
molecul
inhibitor
target
ctermin
domain
capsid
identifi
activ
compound
show
drastic
reduc
infect
infect
cell
flavivirida
famili
contain
mani
relev
pathogen
virus
hepat
c
viru
hcv
dengu
viru
denv
yellow
fever
viru
yfv
west
nile
viru
wnv
tickborn
enceph
viru
tbev
viral
genom
virus
belong
famili
encod
three
structur
protein
core
form
viral
particl
seven
nonstructur
protein
particip
genom
replic
virion
assembl
far
enzymat
activ
elucid
e
protein
crucial
fusion
activ
make
protein
suitabl
antivir
target
eprotein
sever
success
dock
studi
report
kampmann
et
al
perform
dockingbas
vs
ectodomain
denv
eprotein
structur
antivir
activ
low
micromolar
rang
could
measur
two
hit
compound
denv
interestingli
one
compound
also
show
antivir
activ
wnv
yfv
anoth
studi
publish
wang
et
al
highthroughput
dock
led
identif
antivir
thiophenpyrimidin
nm
human
cell
line
poh
et
al
discov
compound
inhibit
dengu
fusion
low
micromolar
rang
dock
million
inhous
compound
yennam
cowork
combin
three
differ
dock
algorithm
identifi
inhibitor
denv
eprotein
collect
thirteen
avail
databas
one
seven
test
molecul
show
valu
micromolar
rang
umamaheswari
et
al
identifi
ten
new
lead
structur
fusion
inhibitor
yfv
use
start
point
design
antivir
drug
yellow
fever
proteasehelicas
anoth
potenti
drugtarget
flavivirida
famili
studi
target
protein
new
inducedfit
dock
program
geniu
develop
takaya
use
discoveri
new
hcv
proteas
inhibitor
shiryaev
perform
dock
studi
compound
nci
databas
cofactor
bind
site
proteas
crystal
structur
wnv
lead
one
biolog
valid
inhibitor
nanomolar
activ
polymeras
key
target
discoveri
antivir
agent
treatment
hcv
flavivirida
infect
pharmacophorebas
approach
follow
kim
et
al
model
hcv
nni
site
iv
built
use
screen
commerci
compound
librari
test
hit
best
compound
show
valu
low
micromolar
rang
dockingbas
vs
studi
lin
cowork
screen
chemic
found
isoxazol
signific
dosedepend
inhibit
hcv
rdrp
activ
replic
talel
et
al
identifi
two
novel
chemotyp
alloster
inhibitor
hcv
molecular
dock
compound
commerci
avail
databas
alloster
musmuca
et
al
use
qsar
score
function
dockingbas
vs
nci
databas
result
one
compound
inhibitori
activ
podvinec
et
al
also
use
molecular
dock
screen
librari
contain
million
commerci
avail
compound
two
bind
site
denv
eight
differ
type
virus
belong
herp
famili
known
infect
human
caus
varieti
diseas
commonli
target
protein
virus
thymidin
kinas
target
like
viral
helicas
proteas
proteinprotein
interfac
replic
protein
also
investig
especi
avail
crystal
structur
viral
protein
basi
vs
effort
regard
new
therapeut
target
exampl
li
et
al
recent
publish
studi
epsteinbarr
nuclear
antigen
propos
target
epsteinbarr
virus
compound
collect
screen
workflow
base
solubl
predict
dock
sever
score
function
like
four
inhibitor
biolog
test
compound
could
identifi
outbreak
sever
acut
respiratori
syndrom
sar
china
nearli
pandem
statu
trigger
huge
amount
effort
regard
develop
therapeut
drug
coronaviru
cov
caus
diseas
develop
drug
sarscov
mostli
two
protein
target
sarscov
spike
protein
protein
sarscov
main
proteinas
mpro
also
call
sarsco
pro
vs
success
use
identifi
optim
compound
inhibit
sarscov
pro
studi
publish
ngoyen
et
al
describ
vs
workflow
two
compound
inhibitori
activ
sarscov
pro
low
micromolar
concentr
could
identifi
achiev
commerci
compound
databas
screen
procedur
involv
filter
predict
toxic
properti
ii
dock
iii
filter
free
energi
calcul
potenti
hbond
format
protein
ligand
iv
cluster
visual
inspect
step
way
vs
success
use
optim
inhibitor
sarsco
pro
demonstr
mukherje
cowork
base
two
micromolar
inhibitor
previous
identifi
structurebas
vs
combin
ligand
structurebas
studi
perform
improv
inhibitori
potenc
analyz
avail
chemic
space
ligandbas
part
screen
consist
similar
search
filter
substructur
substitut
follow
dock
studi
rescor
perform
select
hit
biolog
valid
vs
also
enabl
explor
process
viral
lifecycl
potenti
drug
target
mani
virus
rna
pseudoknot
format
subsequ
ribosom
frameshift
necessari
translat
viral
protein
shown
diminish
ribosom
frameshift
caus
decreas
product
viral
particl
make
potenti
target
fight
viral
infect
exampl
success
vs
park
et
al
could
identifi
compound
bind
sar
pseudoknot
inhibit
rf
sar
virus
purpos
structur
pseudoknot
first
comput
model
dockingbas
procedur
compound
select
biolog
test
lead
one
potent
rf
inhibitor
advent
viral
escap
mutant
one
princip
advers
face
antivir
therapi
possibl
turn
drug
target
viral
protein
inact
wwwdrugdiscoverytodaycom
avoid
one
strategi
target
host
protein
necessari
viru
replic
nonessenti
host
like
inhibit
process
hiv
entri
instead
viral
envelop
glycoprotein
human
receptor
also
target
pereznueno
et
al
develop
valid
combin
structur
dock
ligandbas
qsar
analys
pharmacophor
model
shape
match
vs
workflow
target
receptor
approach
use
select
five
virtual
hit
synthesi
databas
virtual
molecul
could
valid
inhibitor
biolog
test
vs
proven
use
discoveri
new
antivir
drug
advantag
ration
faster
drug
discoveri
process
obviou
especi
antivir
research
sudden
emerg
new
diseas
drug
resist
common
past
year
vs
mainli
use
leaddiscoveri
smaller
extent
compound
develop
optim
virtual
screen
effort
employ
dock
princip
screen
techniqu
less
common
similar
search
valid
ligand
pharmacophorebas
screen
overview
percentag
studi
appli
respect
techniqu
shown
fig
distinct
requir
featur
explain
differ
frequenc
method
employ
major
advantag
dock
vs
util
screen
compound
act
certain
protein
soon
one
crystal
structur
exist
especi
use
earli
lead
discoveri
point
scarc
inform
access
employ
similar
search
method
screen
least
one
known
ligand
must
exist
build
pharmacophor
sever
known
ligand
crystal
structur
cocrystal
ligand
necessari
make
method
difficult
employ
littl
inform
avail
contrast
later
drug
develop
stage
experiment
data
avail
especi
pharmacophor
effici
use
vs
lead
hit
compound
high
structur
variabl
one
main
advantag
similar
search
effici
term
comput
time
especi
comparison
dock
less
suitabl
largescal
virtual
screen
campaign
requir
advantag
disadvantag
report
techniqu
summar
tabl
remain
obviou
drug
develop
process
still
need
improv
far
fast
enough
face
suddenli
appear
viral
diseas
appropri
time
scale
besid
sever
sever
diseas
like
hiv
remain
without
cure
despit
high
expens
research
effort
made
improv
accuraci
vs
method
well
improv
qualiti
avail
experiment
data
achiev
closer
collabor
experiment
theoret
group
mention
promis
advanc
made
identifi
target
host
protein
could
option
avoid
problem
relat
viral
variabl
